Pamela Demain is Executive Director, Corporate Licensing at Merck & Co., Inc. She has been at Merck for twenty-five years. For twelve years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations and research platform technologies. Pam also heads up the relationship development area, which involves initiating new business development opportunities. Prior to her current position, Ms. Demain was in charge of the Business Information & Research Group in the Worldwide Human Health Marketing area of Merck, providing strategic decision support for new and in-line products.

Previous positions at Merck include Corporate Planning, Marketing Communications and Product Management, where she was responsible for the worldwide launch of PRIMAXIN/TIENAM. She joined Merck in 1981 as part of a management training program.

Pamela's pharmaceutical career began in the natural products laboratory of Gruppo Lepetit, an Italian pharmaceutical company, which was then a subsidiary of the Dow Chemical Company. Ms. Demain is a graduate of the University of Massachusetts at Amherst, and holds a M.B.A. in International Business from The American University in Washington, D.C.